Bio-Techne Corp (TECH) has been trending in the recent market news. SWOT has revealed significant insights about the company. Among the highlights is participation in AMP 2024 Annual Meeting & Expo where novel solutions for cancer and carrier screening will be showcased. The company also showed impressive growth in its Q1 2025 earnings while successfully navigating through various growth and challenges. They've launched IVDR certified hematology controls and calibrators, contributing to its corporate prominence. An attention-grabbing aspect was Geneva Capital Management LLC and Royce & Associates LP investment worth $88.27 Million and 17,296 shares in Bio-Techne respectively, indicating trust in TECH's market value. Bio-Techne's stock was also boosted after their Q1 earnings and revenue estimates were topped while Diagnostic unit growth drove Bio-Techne's quarterly profit. StockNews.com raised TECH to Buy. However, some investors experienced losses of 43%. Strategic partnerships and acquisitions such as the proposed acquisition of Lunaphore and partnership with Nikon Instruments Inc. for expanding access to innovative spatial biology services, bolster the company's market position. The company also successfully achieved ISO 13485 certification for its manufacturing facility.
Bio-Techne Corp TECH News Analytics from Thu, 01 Sep 2022 07:00:00 GMT to Fri, 15 Nov 2024 14:01:17 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor -4
